Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infliximab biosimilar - Reliance Life Sciences

Next Previous
Drug Profile

Infliximab biosimilar - Reliance Life Sciences

Alternative Names: BOW-015; Infimab; R-TPR-015

Latest Information Update: 29 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EPIRUS Biopharmaceuticals
  • Developer EPIRUS Biopharmaceuticals; Reliance Life Sciences; Sun Pharmaceutical Industries
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Marketed Plaque psoriasis; Rheumatoid arthritis
  • No development reported Autoimmune disorders

Most Recent Events

  • 01 Sep 2019 Launched for Plaque psoriasis in India (unspecified route), before September 2019
  • 01 Aug 2019 Registered for Plaque psoriasis in India (unspecified route), before August 2019
  • 14 Mar 2019 No recent reports of development identified for preregistration for Autoimmune disorders in Malaysia, Indonesia, Indonesia, Thailand (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top